CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06065059
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:17.631210+00:00
Published At: 2024-08-13T00:00:00+00:00
Record Updated At: 2024-08-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Breast Cancer", "Ovarian Cancer", "Pancreas Cancer", "Prostate Cancer", "BRCA1 Mutation", "BRCA-Mutated Ovarian Carcinoma", "BRCA-Associated Breast Carcinoma", "HRD Positive Advanced Ovarian Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-08-13"
protocolSection.identificationModule.nctId: "NCT06065059"
protocolSection.identificationModule.officialTitle: "Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or Other HRD+ Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.